The firm also announced that it plans to expand its RAS biomarker testing collaboration with Amgen in Europe.
The bank said that although it is forecasting a 17 percent stronger flu season this year, Quidel's influenza sales are only likely to rise 10 percent.
In Science this week: genetically modified flu virus could be key to new live vaccines, and more.
The test is the first in a proposed line of assays that will run on the GeneXpress platform with run times of around 30 minutes.
The firm said that molecular product sales were up 103 percent, driven by the launch of the Solana Group A Strep assay earlier this year.
The real-time PCR-based test runs on the BD Max system and comes in a single tube that snaps into the BD MAX extraction cartridge.
The test runs on the company's Solana instrument, which can process up to 12 patient samples in a 45-minute run.
The investment bank said it has heard positive feedback from early adopters in Europe of GenMark's ePlex system and respiratory panel.
The Alere flu test detected fewer cases of influenza A in a recent study, which researchers attributed to low viral loads.
Although the financial filing sheds increased light on Alere's business, the company is asking for an extension to file its second quarter financial statements.
Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.
The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.
One gene regulates hundreds of others to influence facial development, according to New Scientist.
In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.